Rolfo, Christian http://orcid.org/0000-0002-7860-8417
Giovannetti, Elisa
Martinez, Pablo
McCue, Shannon
Naing, Aung http://orcid.org/0000-0002-4803-8513
Article History
Received: 18 April 2022
Accepted: 17 February 2023
First Online: 8 March 2023
Competing interests
: C.R. has served as an advisory board member for Archer, Inivata, Merck Serono, Bristol-Myers Squibb, and Boston Pharmaceuticals; taken part in speaker events for Merck Sharpe & Dohme, Astra Zeneca, and Roche; received non-financial support from GuardantHealth and grants from the Lung Cancer Research Foundation and Pfizer Oncology collaboration, outside of the submitted work. E.G. reports no competing interests. P.M. was a salaried employee of Sumitomo Pharma Oncology at the time this manuscript was written. S.M. is a salaried employee of Sumitomo Pharma Oncology. A.N. received research funding from NCI, EMD Serono, MedImmune, Healios Onc. Nutrition, Atterocor/Millendo, Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol-Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Eli Lilly, Kymab, PsiOxus, Arcus Biosciences, NeoImmuneTech, ImmuneOncia, and Surface Oncology (paid to institution); was on the advisory boards of CytomX Therapeutics, Novartis, Genome & Company, OncoSec KEYNOTE-695, Kymab, and STCube Pharmaceuticals; and received travel and accommodation expense from ARMO BioSciences. Dr. Naing’s spouse received research funding from the Immune Deficiency Foundation, Jeffery Modell Foundation and chao physician-scientist, and Baxalta (paid to institution) and was on the advisory board of Takeda, CSL, Behring, Horizon and Pharming.